Novartis Selects Qualcomm Lifes 2net Tech to Digitize Clinical Trials

Qualcomm announced that its subsidiary, Qualcomm Life, has been selected by Novartis as a global digital health collaborator for its Trials of The Future program. Qualcomm Life’s 2net Platform will serve as a global connectivity platform for collecting and aggregating medical device data during clinical trials to improve the convenience and speed of capturing study participant data and test results to ultimately gain more trial efficiencies and connected experiences for participants.

The Trials of The Future program is designed to leverage health care technology to improve the experience of clinical trial participants and patients using Novartis products, and provide connectivity with future products marketed by Novartis. Novartis is using the 2net Platform in a recently-launched observational study, evaluating the use of mobile devices with chronic lung disease patients. In this trial, 2net Mobile-enabled smartphones and 2net Hubs collect and aggregate biometric data from medical devices and transmits data to the cloud-based 2net Platform, which securely sends the data to the study coordinator. 

Read the full release here.